Related Experiment Video
Updated: Jun 16, 2025
10:07
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
15.0K
Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments.
Carmelo Scarpignato1,2,3,4, Richard H Hunt5
1Department of Medicine & Surgery, University of Parma, Parma, Italy. carmelo.scarpignato@unipr.it.
Current Gastroenterology Reports
|August 15, 2024
Summary
New potassium-competitive acid blockers (P-CABs) offer improved acid suppression for conditions like GERD and H. pylori infections, addressing limitations of traditional proton pump inhibitors (PPIs). Further long-term safety data is needed for these novel antisecretory drugs.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Proton pump inhibitors (PPIs) are standard for acid-related diseases but have limitations.
- Unmet clinical needs persist in managing GERD, H. pylori, and NSAID-related ulcers.
- Limitations include inconsistent acid suppression and poor control of nighttime acidity.
Purpose of the Study:
- To review the current status and future development of potassium-competitive acid blockers (P-CABs).
- To highlight P-CABs as a new class of antisecretory drugs.
- To compare P-CABs with existing acid suppressants.
Main Methods:
- Literature review of P-CABs and PPIs.
- Analysis of clinical trial data for P-CABs in GERD and H. pylori eradication.
- Comparison of efficacy and safety profiles.
Main Results:
- P-CABs (vonoprazan, tegoprazan, fexuprazan, keverprazan) address unmet needs in acid suppression.
- P-CABs demonstrate similar or superior efficacy to PPIs in GERD and H. pylori eradication.
- Short-term safety of P-CABs is comparable to PPIs; long-term data is pending.
Conclusions:
- P-CABs represent a promising advancement in acid suppression therapy.
- These novel drugs offer potential solutions for managing complex acid-related conditions.
- Further long-term studies are essential to fully establish the safety profile of P-CABs.
Keywords:
H. pylori InfectionFexuprazanGERDKerverprazanLinaprazan glurateP-CABsPPIsTegoprazanUnmet Clinical NeedsVonoprazanZestaprazanMore Related Videos
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
482
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
482
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
940
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
940
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
361
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
361
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
552
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
552